Lenalidomide Consolidation Benefits CLL Patients Post Chemoimmunotherapy
Chemoimmunotherapy followed by lenalidomide consolidation is tolerated and extends PFS and OS in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - August 2, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Does Frontline R2CHOP Reduce CNS Relapse Risk in DLBCL?
There may be prophylactic benefit from using lenalidomide, an orally bioavailable CNS-penetrating agent, combined with R-CHOP in the upfront setting. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
Lenalidomide/Rituximab Combo Effective in Advanced FL
Efficacy of lenalidomide plus rituximab was similar to chemotherapy induction in previously untreated symptomatic FL, with a better safety profile. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma
A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months
KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma
THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomi...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Daratumumab/Carfilzomib Combo Effective in Lenalidomide-Refractory MM
Leah LawrenceJun 4, 2018In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Pomalidomide Combo PVd Ups PFS in Lenalidomide-Exposed Myeloma
Leah LawrenceJun 3, 2018OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - June 3, 2018 Category: Cancer & Oncology Authors: A Source Type: news
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies
THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of death b...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Celgene hunts deals to offset loss of Revlimid patent protection
Cancer treatment behind 63% of revenue could face competition from copycats in 2020 (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 8, 2018 Category: Pharmaceuticals Source Type: news
Immunotherapy Drugs Causing Vision Issues
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss.
The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma.
All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers.
The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - March 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news
Off-label Lenalidomide Might Be Alternative to Thalidomide for Erythema Multiforme Off-label Lenalidomide Might Be Alternative to Thalidomide for Erythema Multiforme
Lenalidomide might be considered as off-label treatment for chronic erythema multiforme (EM) if the adverse effects of thalidomide are not acceptable, according to French researchers.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 7, 2018 Category: Allergy & Immunology Tags: Pharmacist News Source Type: news
Celgene to buy Juno for $9 billion to boost cancer pipeline
(Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Celgene diversifies portfolio with purchase of Juno Therapeutics
Celgene Corp. has agreed to acquire Juno Therapeutics Inc. for about $9 billion, or $87 a share.
The deal bolsters Celgene’s portfolio of blood-cancer drugs.
The announcement comes on the heels of a report that the two companies were finalizing a deal, per The Wall Street Journal.
Summit, New Jersey-based Celgene has been trying to diversify its portfolio to help offset losses it would s uffer if one of its drugs, Revlimid, loses patent protection in the U.S. This particular deal will add a… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 22, 2018 Category: Health Management Authors: Anthony Noto Source Type: news
Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma
Results Support Early Use of KYPROLIS at First Relapse
THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent versus len...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
